CHRS Earnings Prediction
The chart below shows how CHRS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CHRS sees a +0.72% change in stock price 10 days leading up to the earnings, and a -9.31% change 10 days following the report. On the earnings day itself, the stock moves by +0.08%. This data can give you a slight idea of what to expect for the next quarter's release.
CHRS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
70.77M
-5.09%
8.92%
Gross Margin
70.69%
25.92%
25.47%
Operating Margin
-9.02%
-78.98%
-71.42%
Net Margin
-15.19%
-71.43%
-23.59%
EPS
-0.09
-78.05%
-18.18%
No Data Available
CHRS Earnings Analysis
Coherus BioSciences, Inc. Corporation (CHRS.O) Earnings Conference Call
Positive
Revenue Growth Achievement: UDENYCA achieved 100% revenue growth since Q3 2023, reaching $66 million in revenue this quarter.
Revenue Increase Analysis: There was a 30% increase in revenue from Q2 to Q3 this year, demonstrating strong franchise performance.
Sales Growth Success: LOQTORZI sales grew 54% quarter-over-quarter, indicating successful execution against the launch plan.
Quarterly Revenue Increase: Total net product revenue for the quarter was $70.6 million, a 21% increase over Q2.
Cost of Goods Sold Decrease: The company reported a significant decrease in cost of goods sold for Q3 2024, down $12 million from the previous year, contributing to improved gross margins.
Negative
Revenue Growth and Demand Decline: UDENYCA revenue growth was 100% since Q3 2023, reaching $66 million this quarter, but this was offset by a 3% decline in overall franchise demand quarter-over-quarter due to temporary supply interruption.
Net Loss Comparison: The Q3 2024 net loss was $10.8 million or $0.09 per diluted share compared to a net loss of $39.6 million or $0.41 per diluted share for the same period in 2023.
R&D Expense Increase: R&D expenses totaled $21.7 million, an increase of $4 million or 15% from Q3 a year ago, indicating rising costs in product development.
SG&A Expense Increase: SG&A expense in Q3 totaled $34.7 million, an increase of $13.5 million or 28% compared to the prior year, reflecting higher operational costs.
Interest Expense Increase: Interest expense in Q3 was $5.4 million, which reflects an increase of $4.9 million or 48% from Q3 last year, primarily due to the repayment of a $250 million term loan.
CHRS FAQs
How does CHRS typically perform around its earnings report dates?
Is Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CHRS Earning Call Sentiment
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CHRS.O
-9.46%Positive
The earnings call summary highlights significant revenue growth, improved financial health, and effective cost management, which are positive indicators. Despite some supply chain and regulatory challenges, the company is optimistic about future market share gains. The Q&A section addresses concerns with a clear plan for resuming sales and meeting demand, contributing to a positive outlook. Overall, the strong financial performance and optimistic future guidance outweigh the potential risks, suggesting a positive stock price movement in the near term.
